Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients.

Lund JL, Stürmer T, Sanoff HK, Brookhart A, Sandler RS, Warren JL.

Cancer. 2013 Jun 1;119(11):2038-47. doi: 10.1002/cncr.27991. Epub 2013 Mar 19.

2.

Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.

Panchal JM, Lairson DR, Chan W, Du XL.

Clin Colorectal Cancer. 2013 Jun;12(2):113-21. doi: 10.1016/j.clcc.2012.09.007. Epub 2012 Nov 6.

PMID:
23137529
3.

Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524. Epub 2012 Jan 20.

4.

Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.

Mack CD, Carpenter W, Meyer AM, Sanoff H, Stürmer T.

Cancer. 2012 Jun 1;118(11):2925-34. doi: 10.1002/cncr.26622. Epub 2011 Nov 9.

5.

Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Clin Oncol. 2012 Jul 20;30(21):2624-34. doi: 10.1200/JCO.2011.41.1140. Epub 2012 Jun 4.

6.

Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.

McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA.

Clin Colorectal Cancer. 2013 Mar;12(1):62-9. doi: 10.1016/j.clcc.2012.09.001. Epub 2012 Oct 24.

7.

Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.

Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, Fuchs CS.

J Clin Oncol. 2011 Aug 20;29(24):3255-62. doi: 10.1200/JCO.2011.35.0058. Epub 2011 Jul 18. Erratum in: J Clin Oncol. 2012 Jan 20;30(3):343.

8.

Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.

Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D.

Cancer. 2012 Sep 1;118(17):4309-20. doi: 10.1002/cncr.27422. Epub 2012 Jan 31.

9.

Explaining black-white differences in receipt of recommended colon cancer treatment.

Baldwin LM, Dobie SA, Billingsley K, Cai Y, Wright GE, Dominitz JA, Barlow W, Warren JL, Taplin SH.

J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20.

10.

Completion of therapy by Medicare patients with stage III colon cancer.

Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W.

J Natl Cancer Inst. 2006 May 3;98(9):610-9.

11.

Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.

Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, Harrington DP, Fletcher RH.

JAMA. 2010 Mar 17;303(11):1037-45. doi: 10.1001/jama.2010.272.

12.

[Efficacy of oxaliplatin-based adjuvant chemotherapy in stage II and III colorectal cancer with perforation].

Onozawa H, Hatano S, Matsuzawa T, Kuwabara K, Ishiguro T, Sobajima J, Kumamoto K, Fukuchi M, Kumagai Y, Baba H, Ishibashi K, Mochiki E, Ishida H.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1749-51. Japanese.

PMID:
25731317
13.

Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer.

Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM.

Am J Gastroenterol. 2006 Oct;101(10):2308-18.

PMID:
17032196
14.

Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer.

Davila JA, Chiao EY, Hasche JC, Petersen NJ, McGlynn KA, Shaib YH.

Pancreas. 2009 Jan;38(1):e18-25. doi: 10.1097/MPA.0b013e318187eb3f.

15.

Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.

Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.

Jpn J Clin Oncol. 2013 Feb;43(2):132-8. doi: 10.1093/jjco/hys195. Epub 2012 Nov 29.

16.

Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer.

Hershman DL, Buono D, McBride RB, Tsai WY, Joseph KA, Grann VR, Jacobson JS.

J Natl Cancer Inst. 2008 Feb 6;100(3):199-206. doi: 10.1093/jnci/djm320. Epub 2008 Jan 29.

17.

Patterns of Colorectal Cancer Care in the United States: 1990-2010.

Murphy CC, Harlan LC, Lund JL, Lynch CF, Geiger AM.

J Natl Cancer Inst. 2015 Jul 23;107(10). pii: djv198. doi: 10.1093/jnci/djv198. Print 2015 Oct.

PMID:
26206950
18.

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA.

J Clin Oncol. 2011 Sep 1;29(25):3381-8. doi: 10.1200/JCO.2010.34.3426. Epub 2011 Jul 25.

19.

[Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials].

Lamberti C, Lundin S, Bogdanow M, Gorschlüter M, Schmidt-Wolf IG, Sauerbruch T.

Dtsch Med Wochenschr. 2006 Mar 10;131(10):485-90. German.

PMID:
16511737
20.

Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.

Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, Higuera O, Burgos E, Ramos D, Calatrava A, Andrada E, López R, Moreno V, Madero R, Cejas P, Feliu J.

Ann Oncol. 2014 Feb;25(2):398-403. doi: 10.1093/annonc/mdt546. Epub 2013 Dec 18.

Items per page

Supplemental Content

Write to the Help Desk